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Levamisole has previously been identiﬁed as an inhibitor of angiogenesis in vitro and in vivo, but the
mechanism behind the anti-angiogenic behavior has not yet been established. However, one known
eﬀect of levamisole is the inhibition of alkaline phosphatase, and this fact encouraged us to test other
phosphatase inhibitors for their anti-angiogenic eﬀects by using the same method as used to identify
levamisole: an ELISA-based co-culture angiogenesis assay giving quantitative and qualitative results.
Historically, intracellular phosphatases have been associated with the downregulation of signaling
pathways, and kinases with their upregulation, but lately, the phospatases have also been coupled to
positive signaling, which is why inhibition of phosphatases has become associated with
anti-tumorigenic and anti-angiogenic eﬀects. The results obtained in this work reveal several agents
with anti-angiogenic potential and give a strong indication that phosphatase inhibition is linked to
anti-angiogenic activity. An apparent disruption of endothelial tube formation was seen for seven of
eight phosphatase inhibitors tested in the angiogenesis assay. By looking at the morphological results,
it was seen that most of the inhibitors impaired proliferation and elongation of the endothelial cells,
which still had a diﬀerentiated appearance. One inhibitor, PTP inhibitor IV, seemed to impair endothe-
lial cell diﬀerentiation and induced the same morphology as when cells were treated with levamisole,
although at a 200 times lower concentration than that of levamisole. Hence, our work points out com-
pounds with a potential that may be of use in the search for new medical products for the treatment of
malignant tumors, or other conditions where angiogenesis plays a central role.
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ANGIOGENESIS
To grow beyond the size of 1–2 mm
3, a solid
tumor depends on angiogenesis, the develop-
ment of new blood vessels from pre-existing vas-
culature (1). In the adult, angiogenesis is tightly
controlled by a balance between pro- and anti-
angiogenic factors, and the vasculature is
mainly quiescent (2), except during the female
reproductive cycle, wound healing and in rela-
tion to pathological conditions such as cancer,
rheumatoid arthritis and diabetic retinopathy
(3). Pro- and anti-angiogenic factors can derive
from cancer cells, endothelial cells, stromal cells,
the bloodstream and the extracellular matrix
(ECM). Angiogenesis involves the coordination
of several steps: (i) binding of angiogenic stimu-
lating factors [vascular endothelial growth
factor (VEGF) and ﬁbroblast growth factor
(FGF)] to their receptors on endothelial cells,
(ii) secretion of proteases, which degrade the
vascular basement membrane (VBM) and the
surrounding ECM, (iii) endothelial proliferation
and migration, (iv) endothelial diﬀerentiation
and tube formation, (v) reformation of the
VBM, (vi) recruitment of pericytes, which Received 17 March 2009. Accepted 26 October 2009
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49surround and stabilize the newly formed vessel
(4–6).
INHIBITION OF ANGIOGENESIS
An eﬀective approach to starving a tumor is to
inhibit the development of new tumor blood
vessels, and thereby reduce tumor progression.
Several angiogenesis inhibitors combined with
traditional cancer therapy have been shown to
prolong the survival of patients with advanced
cancer. A few of them are now in clinical use
and eﬀective toward some types of cancer (7),
one of them being Bevacizumab (Avastin
 
Roche, Basel, Switzerland), a neutralizing anti-
body against VEGF (8). However, the inhibitors
have been seen to cause serious side eﬀects
(9–11), and identiﬁcation of new angiogenesis
inhibitors with limited toxicity and a broader
eﬃciency is still needed, as well as a further
understanding of endothelial cell signaling
to comprehend the mechanisms of action of
potential inhibitors.
SCREENING ASSAY FOR
IDENTIFICATION OF NEW POTENTIAL
ANGIOGENESIS INHIBITORS
An ELISA-based co-culture angiogenesis assay,
with endothelial cells growing on a layer of
ﬁbroblasts, has previously been developed and
serves as a screening assay for the identiﬁcation
of new potential anti-angiogenic agents (8). The
endothelial cells form a capillary-like network
when propagated for 3 days in co-culture with
ﬁbroblasts. The assay covers several steps in the
angiogenic cascade unlike many previously
established in vitro angiogenesis methods, which
only measure a single step, and in addition to
morphological results the assay provides quanti-
tative ELISA results.
CLASSIFICATION OF ANGIOGENESIS
INHIBITORS
Using the co-culture assay, well-known angio-
genesis inhibitors representing diﬀerent struc-
tural and functional classes could be divided
into two groups according to their eﬀect on
endothelial cell morphology (12). The cells could
be classiﬁed either as separate non-proliferating
cells forming non-canalized short cords without
interconnections or as undiﬀerentiated non-
elongated cells appearing as compact cell clus-
ters. The group of inhibitors causing short cords
of endothelial cells consisted of several known
angiogenesis inhibitors, such as platelet factor 4
(PF4) (13), thrombospondin (TSP) (14), rapa-
mycin (15), suramin (16), TNP-470 (17) and
non-steroidal anti-inﬂammatory drugs (18). In
general, they block proliferation, but their mech-
anisms are quite diﬀerent from one another.
The other group of inhibitors, which caused
cell clusters in the assay, are VEGF antibodies
(7), a VEGF receptor tyrosine kinase inhibitor
SU5614 (19) and the recently identiﬁed angio-
genesis inhibitor levamisole (9, 20). Levamisole
has also been shown to reduce tumor growth
and angiogenesis in nude mice (20).
The mechanism behind the observed anti-
angiogeniceﬀectoflevamisoleremainsunknown,
but because of the very similar cell morphology
induced by the three inhibitors in this group,
they possibly block similar cellular signaling
pathways and the eﬀect of levamisole is very
likely to be found in the pathways triggered by
VEGF receptor binding. One of the known
functions of levamisole is the inhibition of
alkaline phosphatase (21), and this prompted us
to test other phosphatase inhibitors in the assay.
MATERIALS AND METHODS
Chemicals, reagents, and cell lines
Ibandronate sodium salt, AP-conjugated goat anti-
mouse IgG, 5-bromo-4-chloro-3-indolyl phosphate⁄
nitro blue tetrazolium (BCIP⁄NBT) tablets, p-nitro-
phenyl phosphate (p-NPP) tablets, dimethyl sulfoxide
(DMSO), levamisole, and bovine serum albumin were
from Sigma-Aldrich (St. Louis, MO, USA). Clodro-
nate disodium salt, salubrinal, Protein tyrosine phos-
phatase 1B (PTP1B) inhibitor, Shp1⁄2 inhibitor
(NSC87877), PTP inhibitor I, II, and IV were from
Merck (Darmstadt, Germany). MilliQ water equip-
mentwasfromMillipore(Billerica,MA,USA).Mouse
anti-human CD31 monoclonal antibody was from
Monosan(Uden,TheNetherlands).Alkalinesubstrate
buﬀer,mouseanti-humandouble-strandedDNAanti-
body,PBS,andTTNbuﬀerwerefromSSIDiagnostics
(Hillerød, Denmark). Ethanol 96% was from De
Danske Spritfabrikker (Aalborg, Denmark). HEPES
buﬀer, trypsin⁄EDTA, trypsin neutralizing solution
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(HUVEC), normal human dermal ﬁbroblasts
(NHDF), HUVEC media-kit EGM-2 Bulletkit
and NHDF media-kit FGM-2 Bulletkit were from
LONZA (Basel, Switzerland). Recombinant human
basic ﬁbroblast growth factor (hFGF-B), and recom-
binant human VEGF were from R & D Systems
(Minneapolis, MN, USA). Precision plus pre-stained
molecular weight marker was from Bio-Rad
(Hercules, CA, USA).
Preparation of NHDF
NHDF were cultured in 75 cm
2 culture ﬂasks at
37  C, 5% CO2 and 90% humidity in NHDF stan-
dard medium (FGM-2 Bulletkit) consisting of 100 ml
ﬁbroblast basal medium-2 (FBM-2) supplemented
with 0.1 ml human basic ﬁbroblast growth factor
(hFGF-B), 0.1 ml insulin, 0.1 ml gentamicin⁄ampho-
tericin (GA-1000) and 2% fetal bovine serum (FBS).
Before harvesting the cells with trypsin⁄EDTA, they
were washed 2 · 1 min with PBS. After a few min-
utes, trypsin⁄EDTA was neutralized with PBS. The
suspension was centrifuged 10 min at 200 g and the
pellet was resuspended in a known volume of FBM-2
medium before counting. Cells were seeded in a
96-microwell plate with 10
3 cells in 100 ll NHDF
standard medium per well and incubated for 3 days.
Preparation of HUVECs
HUVECs were cultured in 25 cm
2 culture ﬂasks at
37  C, 5% CO2 and 90% humidity in HUVEC stan-
dard medium (EGM-2 Bulletkit) consisting of 100 ml
endothelial basal medium-2 (EBM-2) supplemented
with 0.1 ml ascorbic acid, 0.4 ml hFGF-B, 0.1 ml
recombinant3 insulin-like growth factor (R
3-IGF)-1,
0.1 ml GA-1000, 0.1 ml heparin, 0.1 ml human epi-
dermal growth factor (hEGF), 0.1 ml VEGF, 0.04 ml
hydrocortisone and 2% FBS. The cell was culture
incubated until the cells reached 70–90% conﬂuence
after approximately 3 days. Before harvesting,
the cells were washed 1 · 1 min with HEPES-BSS.
Trypsin⁄EDTA was added to the cells and incubated
for 2 min at 37  C to promote the detachment of
cells. Trypsin was neutralized with TNS and the
suspension was centrifuged for 5 min at 200 g. The
pellet was resuspended in a known volume of EBM-2
medium before counting and the cells were now ready
to be seeded on top of the ﬁbroblasts in the microwell
plate (see next section).
Co-culture of NHDF and HUVEC
A previously published angiogenesis assay was
performed essentially as described by Friis et al. (12,
22) and outlined brieﬂy below. After 3 days of
incubation in the 96-microwell plate, the ﬁbroblasts
had created a dense layer at the bottom of each well.
The medium was removed and on top of the ﬁbro-
blasts 10
3 endothelial cells were added to each well in
135 ll TFSM2 + 10% (a reduced medium consisting
of 100 ml EBM-2 medium supplemented only with
0.11 ml ascorbic acid, 0.11 ml GA-1000, 0.11 ml
hEGF and 2.2% FBS) with either the presence of
15 ll phosphatase inhibitor in diﬀerent concentra-
tions, 15 ll phosphatase inhibitor solvent only
(milliQ water or DMSO) or 15 ll EBM-2 medium
only. After 3 days of co-culture, the ELISA could be
performed.
ELISA on co-culture cells
The medium was removed from the plate after 3 days,
and the cells were washed for 1 min with PBS,
200 ll⁄well, followed by ﬁxation with 100 ll⁄well
96% ethanol ()20  C) for 15 min. All further incuba-
tions were performed at room temperature using
200 ll⁄well for washing and blocking unless other-
wise stated. The cells were washed 2 · 1 min with
TTN buﬀer followed by blocking of non-speciﬁc
binding for 1 h with the same buﬀer. Primary anti-
bodies were diluted in TTN buﬀer and plates were
incubated either at 4  C overnight or for 1 h at room
temperature with 100 ll⁄well of either mouse anti-
human dsDNA (1:20 000), mouse anti-human CD31
(1:250) or TTN buﬀer, followed by washing
3 · 1 min with TTN. 100 ll AP-conjugated goat
anti-mouse IgG (1:1000) was added to all the wells
and incubated for 1 h and again the wells were
washed 3 · 1 min with TTN. To quantify the
detected antigen, 100 ll1m g⁄ml p-NPP dissolved in
alkaline substrate buﬀer with 1 mM levamisole (as an
inhibitor of endogenous AP) was added to each well.
The absorbance was read after 30, 60 and 120 min at
405 nm with background subtraction at 650 nm using
a Versamax plate reader (MDC, Sunnyvale, CA,
USA). By deﬁnition, a compound acts as a speciﬁc
angiogenesis inhibitor if the relative absorbance
(absorbance measured with inhibitor present in med-
ium in relation to absorbance measured with no
inhibitor, but with the presence of inhibitor solvent in
the medium) is at the same time below 0.8 for detec-
tion of CD31 and above 0.8 for detection of dsDNA.
The deﬁnition was based on results obtained in the
co-culture assay with well-known angiogenesis inhibi-
tors and the fact that the measurement of dsDNA
indicates the number of ﬁbroblasts (23).
Immunostaining of co-culture cells
After ELISA readings, the wells were washed
3 · 1 min with TTN followed by development for 1 h
in 1 mg⁄ml BCIP⁄NBT dissolved in milliQ water.
The wells were washed 2 · 1 min and further stored
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inspected in an Olympus (Tokyo, Japan) IX 70 micro-
scope and photographed with an Olympus DP12
digital camera at ·40 magniﬁcation.
RESULTS
The aim of the present work was to screen
diﬀerent phosphatase inhibitors for their eﬀect
on endothelial cell network formation, and
thereby identify new potential anti-angiogenic
compounds. The tested inhibitors are listed in
Table 1 together with previously reported cellu-
lar eﬀects and the phosphatases they most
potently inhibit. The inhibitors represent a
broad spectrum and were chosen according to
availability and assumed targets. The eﬀects of
the inhibitors were analyzed using an assay with
the advantage of gaining morphological results
and quantitative ELISA results from the same
well. The ELISA results reveal the inhibitor’s
eﬀect on cell number, and combining them with
the morphological staining results gives details
on how the cells have been aﬀected (prolifera-
tion, diﬀerentiation and elongation).
The endothelial cells were detected using
CD31 antibody after 3 days of incubation in
co-culture with or without phosphatase inhibi-
tors, and for the detection of all cells present in
the well (NHDF and HUVEC), an antibody
against dsDNA was used. In the wells, the endo-
thelial cells account for only around 1% of the
total number of cells present, therefore dsDNA
staining is actually a reﬂection of the number of
ﬁbroblasts in the well. The dsDNA is thereby
used to determine if the inhibitors have a toxic
eﬀect on the ﬁbroblasts.
The screening identiﬁed several compounds
with anti-angiogenic potential. A suitable
concentration range for each compound was
determined by preliminary experiments and
thereafter, an IC50 value (the concentration of
the phosphatase inhibitor when 50% of the
endothelial cell network formation had been
inhibited compared to control) was calculated
(Table 2). The obtained IC50 values extend over
a large range of concentrations. The most eﬀec-
tive of the tested compounds (with the lowest
IC50) were PTP inhibitor I and PTP inhibitor II,
both with an IC50 value of 3.7 lM and the com-
pound with the highest IC50 was clodronate
(800 lM). The PTP1B inhibitor was the only
tested phosphatase inhibitor which had no eﬀect
on the cells in the angiogenesis assay. A few of
the inhibitors had a toxic eﬀect on the ﬁbro-
blasts, which indicates that they are not endo-
thelial cell speciﬁc and will be less suitable
candidates for an anti-angiogenic product.
These were ibandronate at concentrations ‡100
lM, PTPi I ‡ 10 lM, and PTPi II ‡100 lM.
The ELISA results for all the tested com-
pounds are illustrated as relative absorbances
compared to control in Figs. 1 and 3. The eﬀect
of phosphatase inhibitors dissolved in milliQ
water is shown in Fig. 1 and is normalized to a
control where 10% milliQ water was added to
the medium instead of 10% phosphatase inhibi-
tor. All the inhibitors had a strong reducing
eﬀect on the endothelial cell proliferation
(CD31) with a relative absorbance around 0.4,
hence below 0.8, which is the limit according to
earlier ﬁndings regarding the inhibitory eﬀect
on the endothelial cells (23). The relative absor-
bance measured with dsDNA antibody, indicat-
ing the proliferation of ﬁbroblasts, shows that
NSC87877 and clodronate do not aﬀect the
ﬁbroblasts (relative absorbance higher than
0.8). Ibandronate, however, has the same inhibi-
tory eﬀect on the ﬁbroblasts as on the endothe-
lial cells.
Looking at the morphological results obtained
from CD31 immunostaining, NSC87877 and
clodronate induce the endothelial cells to obtain
shortcordmorphologywithoutinterconnections
(Fig. 2B,C) compared to the control (Fig. 2A).
The cells have a diﬀerentiated shape, but are not
elongated as seen in the control. The morphol-
ogyobtainedisverydiﬀerentfromthecellcluster
morphology seen when 2 mM levamisole is
present (Fig. 2F), which indicates that these
phosphatase inhibitors use an anti-angiogenic
mechanism diﬀerent from that of levamisole and
VEGF antibody. Ibandronate gave mixed
morphological results depending on its concen-
tration; 1 lM induced clusters and 100 lM
inducedshortcords(Fig. 2D,E).
In Fig. 3 the eﬀects of the phosphatase inhibi-
tors dissolved in 0.1% DMSO are illustrated as
relative absorbances normalized to control
(0.1% DMSO). The PTP1B inhibitor is shown
in the highest tested concentration (a higher
concentration was not possible because it would
result in a too high DMSO concentration), and
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52   2009 The Authors Journal Compilation   2009 APMISTable 1. Phosphatase inhibitors tested in the assay listed along with their chemical structure, their reported
eﬀects and the phosphatases they inhibit
Inhibitor Target
phosphatase
Chemical structure Previously known
cellular eﬀects
of the inhibitor
Levamisole Diﬀerent
isoforms
of AP
N
S N
Capillary tube
formation (20)
Apoptosis (39)
(endothelial cells)
NSC87877 Shp2, Shp1
N
SO3H
OH
N
N
SO3H
ERK phosphorylation
Cellular motility
(cancer cells) (27)
Salubrinal PP1⁄GADD34
complex
N
H
N
S
H
N
CCl3
H
N
O
Apoptosis (31)
(cancer cells)
Apoptosis (32)
(beta cells)
PTP1B
inhibitor
PTP1B S
NH
O O
S
NH
O
O S
N
O
O Br
OH
Br C2H5
Insulin signaling
Akt phosphorylation
(hamster
ovary cells) (35)
Clodronate Bone AP
O O
Cl Cl
OH
OH HO
HO
Proliferation
Apoptosis
(endothelial cells)
(30)
Ibandronate Bone AP
N
HO
P
P
OH
OH
OH
OH
O
O
Proliferation
Apoptosis
(endothelial
cells) (30)
PTP
inhibitor I
Shp1
PTP1B
OH
O
Br
Not reported
PTP
inhibitor II
Shp1
OCH3
O
Br
Not reported
PTP
inhibitor
IV
Shp2
PTP1B N
H
S
CF3
O O
H
N
S
F3C
O O Capillary formation
(endothelial
cells) (38)
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both CD31 and dsDNA are higher than 0.8.
The CD31 immunostaining results conﬁrm that
the PTP1B inhibitor has no eﬀect on the cells
(Fig. 4B) compared to the control (Fig. 4A).
PTPi IV also has both CD31 and dsDNA above
0.8, but when compared with the morphological
results (Fig. 4D), it is observed that the inhibi-
tor had an inhibitory eﬀect on the endothelial
cells, despite the high CD31 detection in the
ELISA procedure. The reason for this is that
under these circumstances, the cells form multi-
cellular clusters (same morphology as levami-
sole and VEGF antibody), which can result in a
misleading high absorbance as the proliferation
is not aﬀected. This shows how important it is
to compare the quantitative ELISA results with
the morphological⁄qualitative results. This com-
parison has been made systematically with all
the tested compounds regarding the detection of
both dsDNA and CD31.
Salubrinal only had a minor eﬀect on the
endothelial cells at the highest possible concen-
tration (20 lM) according to the ELISA results
(Fig. 3). The immunostaining results show that
the minor inhibitory eﬀect was on elongation, as
the cells are detected as short diﬀerentiated
cords without interconnections (Fig. 4C). The
compounds, PTPi II and PTPi I, have a very
eﬀective inhibitory eﬀect on the endothelial cells
at 10 lM. The endothelial cells treated with
these compounds are almost absent (Fig. 4E,F),
which indicates a rather toxic eﬀect. Especially,
PTPi I also has an inhibitory⁄toxic eﬀect on the
ﬁbroblasts. Which endothelial cell morphology
these compounds induce is diﬃcult to determine
because either they almost erase the cells or they
have no eﬀect on the normal network.
DISCUSSION
The work covered in this article describes diﬀer-
ent phosphatase inhibitors (Table 1) that were
assayed for the eﬀect on endothelial cell
network formation in an in vitro co-culture
angiogenesis assay. The background for testing
phosphatase inhibitors was the identiﬁcation of
the anti-angiogenic activity of the AP-inhibitor
Table 2. Results obtained when HUVECs were treated with phosphatase inhibitors in the co-culture angio-
genesis assay
Inhibitor IC50 Number of tests Cell morphology
Levamisole ND 2 (n = 4) Clusters (2 mM)
NSC87877 0.23 ± 0.06 mM 4 (n = 8) Short cords (0.2 mM)
Salubrinal 42 ± 9 lM
1 3 (n = 6) Short cords (20 lM)
PTP1B inhibitor No inhibition 2 (n = 4) Normal network at all
tested concentrations
Ibandronate ND 3 (n = 6) Short cords⁄clusters
(1 lM, 10 lM and 0.1 mM)
Clodronate 0.8 ± 0.2 mM 3 (n = 6) Short cords (1 mM)
PTP inhibitor I 3.7 ± 0.2 lM 2 (n = 4) Dead cells (10 lM)
PTP inhibitor II 3.7 ± 0.1 lM 2 (n = 4) Dead cells (10 lM)
PTP inhibitor IV 40 ± 15 lM
1 3 (n = 6) Clusters (10 lM)
The concentration causing 50% inhibition of endothelial cell network formation (IC50) has been calculated from
two to four independent tests, each time in duplicate (n = 4–8), and is illustrated in the Table ±SD. ND, not
determined. The visualized cell morphology is stated along with the concentrations where the stated cell mor-
phology is observed.
1IC50 was found by extrapolation.
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Fig. 1. The phosphatase inhibitors NSC87877, clodr-
onate and ibandronate impair HUVEC proliferation.
ELISA results showingthe inhibitory eﬀect of0.2 mM
NSC87877, 1 mM clodronate and 0.1 mM ibandro-
nate on HUVEC (CD31) and NHDF (dsDNA) grown
in co-culture. Data are presented as relative absor-
bance (tested compound⁄milliQ water), from three to
four independent experiments ± SD. Each experi-
mentwas performed induplicate, n = 6–8.
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anti-angiogenic functions has previously been
focused on the inhibition of kinases and thereby
phosphorylation in cellular signaling pathways,
but lately, the inhibition of phosphatases
has also gained greater attention. The results
obtained in this work reveal several potential
anti-angiogenic agents, and give a strong indica-
tion that phosphatase inhibition is linked to
anti-angiogenic activity because an obvious
inhibition of endothelial tube formation was
seen with seven of eight phosphatase inhibitors
tested in the angiogenesis assay. In general, they
inﬂuenced the cells to obtain the short cord
morphology, which is an indication of blockage
of endothelial cell proliferation, elongation and
cell interconnections. Only PTPi IV induced dis-
tinct cell clusters, which is a sign of an inhibition
of cell diﬀerentiation rather than proliferation.
This is the morphology also seen when cells are
treated with levamisole or VEGF antibody, and
it indicates that PTPi IV has an eﬀect in the
pathways downstream of VEGFR2. Cell clus-
ters were also seen with ibandronate treatment,
but not to the same extent.
The endothelial cell morphology, which the
phosphatase inhibitors induce, is also listed in
Table 2, and in Table 1, earlier ﬁndings on
cellular eﬀect of the tested phosphatase inhibi-
tors are noted brieﬂy. These eﬀects will be elab-
orated in the following section.
NSC87877 is a potent inhibitor of Shp2, a
phosphatase known to promote several signal-
ing pathways (22, 24–26). This inhibitor has
previously been found by Chen et al. (27) to
reduce viability of a breast cancer cell line, and
they also detected an NSC87877 inhibition of
EGF-induced Shp2 activity in these cells. Shp2
has also been coupled to VEGFR2 signaling
pathways through Gab1 leading to Src activa-
tion resulting in increased migration and capil-
lary formation (28). Testing NSC87877 in the
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Fig. 3. Eﬀects of the PTP1B inhibitor, salubrinal,
PTPi IV, PTPi II and PTPi I in the co-culture assay.
ELISA results are illustrated when HUVEC (CD31)
and NHDF (dsDNA) were treated with DMSO 0.1%
(control), 60 lM PTP1B inhibitor, 20 lM salubrinal,
10 lM PTPi IV, 10 lM PTPi II and 10 lM PTPi I.
Data are presented as relative absorbance (tested
compound⁄milliQ water) from two to three indepen-
dent experiments ± SD. Each experiment was per-
formed in duplicate, n = 4–6.
A B C 
D E  F 
Fig. 2. Immunostaining with CD31 antibody visualized the eﬀects of NSC87877, clodronate and ibandronate on
the endothelial cell network formation. Cells were treated with (A) milliQ water (control), (B) 0.2 mM
NSC87877, (C) 1 mM clodronate, (D) 100 lM ibandronate, (E) 1 lM ibandronate and (F) 2 mM levamisole.
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inhibition of the endothelial cell network devel-
opment (IC50 = 0.23 mM). The individual cells
had a diﬀerentiated appearance, but they were
unable to make interconnections and were not
elongated as untreated cells. NSC87877-induced
endothelial cell inhibition resulted in a morphol-
ogy very diﬀerent from that of levamisole,
which produces cell clusters, a morphology
also seen when cells are treated with the VEGF
antibody. However, it is still possible that
NSC87877 aﬀects the VEGF-induced signaling
pathways, even though a morphology diﬀerent
from that with the VEGF antibody is obtained.
VEGFR 2 binding activates a number of signal-
ing pathways (29) and the antibody inhibits
them all by blocking binding of VEGF to
its receptor. The morphology seen with
NSC87877-treated cells could result from only
one or a few of the pathways being inhibited,
possibly a component downstream of the VEGF
receptor, e.g. Shp2.
The bisphosphonates, clodronate and ibandr-
onate, also had a clear eﬀect on the endothelial
cells, although with a rather high IC50 of clodro-
nate (800 lM). It was not possible to obtain an
IC50 value of ibandronate because the results did
not give a linear curve, but the immunostaining
results clearly show that it is a very potent endo-
thelial cell inhibitor, giving rise to the short cord
morphology as well as to the cell cluster mor-
phology. Fournier et al. (30) also made the
observations that ibandronate and clodronate
have an inhibitory eﬀect towards angiogenesis,
in vitro and in vivo, by inhibiting proliferation
and inducing apoptosis. The endothelial cell
inhibitory mechanisms of ibandronate and
clodronate have still not been elucidated.
Salubrinal has been identiﬁed as an inhibitor
of the PP1⁄GADD34 complex, which dep-
hosphorylates eukaryotic translation initiation
factor 2a (eIF2a). It has been connected with
cell protective as well as pro-apoptotic functions
in a cancer cell line (31) and in primary pancre-
atic beta-cells (32), respectively. Results in this
work indicate that Salubrinal, at concentrations
at 20 lM, has a minor inhibitory eﬀect on the
endothelial cells in the co-culture angiogenesis
assay (IC50 =4 2lM, calculated by extrapola-
tion), inducing a reduced endothelial network
formation and short cord morphology. Whether
the inhibitory eﬀect is a result of apoptosis, as
seen with the primary beta-cells, cannot be
determined from our results, but the morpho-
logy obtained indicates inhibition of prolifera-
tion rather than a pro-apoptotic behavior.
The PTP1B inhibitor did not seem to have
any inhibitory eﬀect on the endothelial cells in
the co-culture angiogenesis assay. However, the
highest possible tested concentration was only
A  B  C 
D  E  F 
Fig. 4. Immunostaining with CD31 antibody visualized the eﬀects of the PTP1B inhibitor, salubrinal, PTPi IV,
PTPi II and PTPi I on the endothelial cell network formation. Cells were treated with (A) DMSO 0.1% (control),
(B) 60 lM PTP1B inhibitor, (C) 10 lM PTPi IV, (D) 20 lM salubrinal, (E) 10 lM PTPi II and (F) 10 lM
PTPi I.
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would otherwise become too concentrated.
Thus, whether the PTP1B inhibitor would inhi-
bit the cells at a higher concentration is not
known from this work. A previous study
suggests that inhibiting PTP1B induces a
pro-angiogenic eﬀect, i.e. a promotion of endo-
thelial cell proliferation and migration (33). In
ﬁbroblasts, however, PTP1B inhibition has been
seen to result in a decreased cell migration (34).
The speciﬁc PTP1B inhibitor used in this work
has been seen to stimulate insulin signaling and
Akt phosphorylation in ovary cells (35), but no
references regarding eﬀects on endothelial cells
have been found.
PTPi I and PTPi II have both been shown to
be potent inhibitors of Shp1, a phosphatase
which inhibits VEGFR2 phosphorylation, and
hence is a negative signaling component (36).
However, the phosphatase inhibitors were the
most eﬀective angiogenesis inhibitors tested in
this assay, indicating that they also inhibit a
positive signaling component, or that Shp1 also
has a positive eﬀect on the cells. PTPi I and
PTPi II also were shown to have a lethal and
not only an inhibitory eﬀect on the endothelial
cells and ﬁbroblasts (from 1 to 10 lM), which
may make them less useful as a medical
product.
In the assay, PTPi IV also turned out to be an
eﬃcient endothelial inhibitor, disturbing the
network at 10 lM and inducing the cell cluster
morphology as seen with levamisole and VEGF
antibody. PTPi IV has been shown amongst
others to be a potent inhibitor of Shp2 (37), as
has also NSC87877. However, they induced
diﬀerent cell structures in the co-culture angio-
genesis assay. Typically, the phosphatase inhi-
bitors aﬀect a large panel of diﬀerent
phosphatases. This could be the reason why we
see diﬀerent morphological results from PTPi
IV and NSC87877. Also, previously, PTPi IV
has been observed to impair capillary-like
formation in vitro (38).
In conclusion, several phosphatase inhibitors
were found to exert considerable angiogenesis
inhibition in vitro. The inhibitory eﬀects of such
inhibitors will not be tumor vessel-speciﬁc, but
can be expected to aﬀect ongoing angiogenesis.
Compared with other angiogenesis inhibitors
like Avastin, small molecule inhibitors may oﬀer
some advantages. Avastin is administered as
injections, whereas small molecule inhibitors
may be taken orally. Avastin may give rise to
antibody formation, and such antibodies may
obliterate the therapeutic eﬀect and give rise to
adverse reactions. On the other hand, small
molecule inhibitors may aﬀect phosphatases
and kinases in many diﬀerent cell types and thus
cause undesirable side reactions. The assay used
here gives a preliminary evaluation of such
eﬀects, as the deﬁnition of angiogenesis inhibi-
tion in the assay relies on comparison of the
relative eﬀects on endothelial cells (HUVEC)
and the general cytotoxic actions on ﬁbroblasts
(NHDF) and endothelial cells.
Summing up, the testing of a range of diﬀer-
ent phosphatase inhibitors clearly showed that
amongst them are several anti-angiogenic
agents, which may have the potential to be a
new medical product. The clinically tolerable
doses of most of the inhibitors are not known.
An elucidation of their angiogenic inhibitory
mechanisms and their eﬀects in vivo, especially
in comparison with VEGF antibodies, will be
an obvious area for future research in the search
for new clinically useful therapeutic anti-
angiogenic drugs.
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